Skip to content
OpenCapital
Get started

Relay Therapeutics, Inc. RLAY EBITDA

EBITDA at other companies

Celcuity logo
CelcuityCELC
-$50.46M-39.8%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$25.58M+193%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$102.98M-38.6%
LQD
Liquidia CorporationLQDA
$62M+277%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K—
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.8B+300%

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0×0.0×
Current ratio22.1×+2.2×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

−$78.6Mebit+
$504.0KDepreciation Depletion & Amortization
=-$78.09M

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s EBITDA?
Relay Therapeutics, Inc. (RLAY) reported EBITDA of -$78.09M in Q1 2026.
How has Relay Therapeutics, Inc.'s EBITDA changed year-over-year?
Relay Therapeutics, Inc.'s EBITDA increased by 6.7% year-over-year, from -$83.66M to -$78.09M.
What is the long-term trend for Relay Therapeutics, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s EBITDA has grown at a -4.6% compound annual growth rate (CAGR), from -$360.77M to -$299.18M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.